title: Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
abstract: Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms. We analyzed the incidence and prognostic value of TET2 point mutations and other genomic alterations by direct sequencing and single nucleotide polymorphism microarray analysis in 111 de novo acute myeloid leukemia, who had all achieved complete remission (CR). Mutations were observed in 19 (17%) of the 111 patients compared with 10 (27%) of 36 patients who had failed to achieve CR (P = .2). In the 111 patients who had achieved CR, TET2 alterations were only significantly associated with NPM1 mutations but not with other pretreatment characteristics. TET2 gene status was not significantly correlated with disease-free survival and overall survival, both in the entire cohort and in patients with normal karyotype.
authors.affiliation: Laboratoire d'hématologie, Centre Hospitalier Regional Universitaire de Lille, Boulevard du Professeur Leclercq, Lille Cedex, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Nibourel
authors.forename: Olivier
authors.initials: O
authors.lastname: Kosmider
authors.forename: Meyling
authors.initials: M
authors.lastname: Cheok
authors.forename: Nicolas
authors.initials: N
authors.lastname: Boissel
authors.forename: Aline
authors.initials: A
authors.lastname: Renneville
authors.forename: Nathalie
authors.initials: N
authors.lastname: Philippe
authors.forename: Hervé
authors.initials: H
authors.lastname: Dombret
authors.forename: François
authors.initials: F
authors.lastname: Dreyfus
authors.forename: Bruno
authors.initials: B
authors.lastname: Quesnel
authors.forename: Sandrine
authors.initials: S
authors.lastname: Geffroy
authors.forename: Samuel
authors.initials: S
authors.lastname: Quentin
authors.forename: Catherine
authors.initials: C
authors.lastname: Roche-Lestienne
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Cayuela
authors.forename: Christophe
authors.initials: C
authors.lastname: Roumier
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.forename: William
authors.initials: W
authors.lastname: Vainchenker
authors.forename: Olivier A
authors.initials: OA
authors.lastname: Bernard
authors.forename: Jean
authors.initials: J
authors.lastname: Soulier
authors.forename: Michaëla
authors.initials: M
authors.lastname: Fontenay
authors.forename: Claude
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D015994:Incidence; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D000090243:Nucleophosmin; D020411:Oligonucleotide Array Sequence Analysis; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012074:Remission Induction; D015996:Survival Rate; D014178:Translocation, Genetic / Q000235:genetics*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C000716967:NPM1 protein, human; D011518:Proto-Oncogene Proteins; D000090243:Nucleophosmin; D049308:Dioxygenases; C541081:TET2 protein, human